Cargando…

HGG-01. INFANT-TYPE HEMISPHERIC GLIOMA: NEW MOLECULAR ALTERATIONS AND PRECISION-MEDICINE TREATMENT

INTRODUCTION: Infant-type hemispheric glioma, harboring alterations in the receptor tyrosine kinases ALK, ROS1, NTRK and MET, is a new subtype of Pediatric-type diffuse high-grade gliomas in the 2021 WHO classification of CNS tumors. It has important clinical therapeutic value with specialized thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Wanming, Yuan, Li, Zeng, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260234/
http://dx.doi.org/10.1093/neuonc/noad073.150
_version_ 1785057820388884480
author Hu, Wanming
Yuan, Li
Zeng, Jing
author_facet Hu, Wanming
Yuan, Li
Zeng, Jing
author_sort Hu, Wanming
collection PubMed
description INTRODUCTION: Infant-type hemispheric glioma, harboring alterations in the receptor tyrosine kinases ALK, ROS1, NTRK and MET, is a new subtype of Pediatric-type diffuse high-grade gliomas in the 2021 WHO classification of CNS tumors. It has important clinical therapeutic value with specialized therapeutic drugs. Here, we presented 3 cases of infant-type hemispheric glioma. Patient1 with EML4-ALK fusion which often appeared in lung cancer, the other 2 patients have new molecular alterations which has not been reported before (Patient2 has both NTRK1-TP53/TP53-NTRK1 fusions and p53 protein showed characteristic cytoplasm positive; Patient3 presented a brand-new ALK-QKI fusion combined with ALK mutation and focal SMARCB1 deletion. All these 3 cases received corresponding targeted therapy and have a good recovery and normal neurologic function till now. METHODS: Immunohistochemistry. Fluorescent in situ hybridization. Whole-transcriptome sequencing. RESULTS: Case 1: 8 months, male, right semiovale center occupation. HISTOPATHOLOGY: High-grade neuroepithelial neoplasm. IHC: GFAP (only few cells+), Olig2(-), S100(+), CD56(+), Syn(-), NSE(focal+), NeuN(-), CD34(-), INI-1(+), Ki67(10%+). Characteristic Molecular Information: EML4-ALK fusion. Follow-up: 15 months, alive. Case 2: 3 years, female, insular lobe occupation. HISTOPATHOLOGY: Gliosarcoma. IHC: GFAP(partly+), Olig2(partly+), Vimentin(+), P53(cytoplasm+), pan-TRK(+), Ki67(25%+). Reticular fiber staining showed biphasic tissue pattern with reticulin-rich sarcomatous and reticulin-free gliomatous elements. Characteristic Molecular Information: NTRK1-TP53 and TP53-NRTK1 fusion. Follow-up: 27 months, alive. Case 3: 3 years, male, left parietal occipital lobe occupation. HISTOPATHOLOGY: GBM and AT/RT. IHC: GFAP(partly+), Olig2(partly+), INI-1(partly-), BRG1(+), SYN(-), CD34(-), BRAF(-), S100(-), CK(-), H3K27M(-), IDH1(-), P53(40%+), ATRX(+), pan-TRK(-), ALK(+), Ki67(30%+). Characteristic Molecular Information: ALK mutation, ALK-QKI fusion, RAD51C mutation and focal SMARCB1(INI-1) deletion. Follow-up: 14 months, alive. Conclusion: Infant-type hemispheric glioma is a special kind of glioma, which is particularly suitable for precision-medicine treatment approaches. Their overall survival is good compared with other three pHGG subtype.
format Online
Article
Text
id pubmed-10260234
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-102602342023-06-13 HGG-01. INFANT-TYPE HEMISPHERIC GLIOMA: NEW MOLECULAR ALTERATIONS AND PRECISION-MEDICINE TREATMENT Hu, Wanming Yuan, Li Zeng, Jing Neuro Oncol Final Category: High Grade Glioma/Gliomatosis Cerebri - HGG INTRODUCTION: Infant-type hemispheric glioma, harboring alterations in the receptor tyrosine kinases ALK, ROS1, NTRK and MET, is a new subtype of Pediatric-type diffuse high-grade gliomas in the 2021 WHO classification of CNS tumors. It has important clinical therapeutic value with specialized therapeutic drugs. Here, we presented 3 cases of infant-type hemispheric glioma. Patient1 with EML4-ALK fusion which often appeared in lung cancer, the other 2 patients have new molecular alterations which has not been reported before (Patient2 has both NTRK1-TP53/TP53-NTRK1 fusions and p53 protein showed characteristic cytoplasm positive; Patient3 presented a brand-new ALK-QKI fusion combined with ALK mutation and focal SMARCB1 deletion. All these 3 cases received corresponding targeted therapy and have a good recovery and normal neurologic function till now. METHODS: Immunohistochemistry. Fluorescent in situ hybridization. Whole-transcriptome sequencing. RESULTS: Case 1: 8 months, male, right semiovale center occupation. HISTOPATHOLOGY: High-grade neuroepithelial neoplasm. IHC: GFAP (only few cells+), Olig2(-), S100(+), CD56(+), Syn(-), NSE(focal+), NeuN(-), CD34(-), INI-1(+), Ki67(10%+). Characteristic Molecular Information: EML4-ALK fusion. Follow-up: 15 months, alive. Case 2: 3 years, female, insular lobe occupation. HISTOPATHOLOGY: Gliosarcoma. IHC: GFAP(partly+), Olig2(partly+), Vimentin(+), P53(cytoplasm+), pan-TRK(+), Ki67(25%+). Reticular fiber staining showed biphasic tissue pattern with reticulin-rich sarcomatous and reticulin-free gliomatous elements. Characteristic Molecular Information: NTRK1-TP53 and TP53-NRTK1 fusion. Follow-up: 27 months, alive. Case 3: 3 years, male, left parietal occipital lobe occupation. HISTOPATHOLOGY: GBM and AT/RT. IHC: GFAP(partly+), Olig2(partly+), INI-1(partly-), BRG1(+), SYN(-), CD34(-), BRAF(-), S100(-), CK(-), H3K27M(-), IDH1(-), P53(40%+), ATRX(+), pan-TRK(-), ALK(+), Ki67(30%+). Characteristic Molecular Information: ALK mutation, ALK-QKI fusion, RAD51C mutation and focal SMARCB1(INI-1) deletion. Follow-up: 14 months, alive. Conclusion: Infant-type hemispheric glioma is a special kind of glioma, which is particularly suitable for precision-medicine treatment approaches. Their overall survival is good compared with other three pHGG subtype. Oxford University Press 2023-06-12 /pmc/articles/PMC10260234/ http://dx.doi.org/10.1093/neuonc/noad073.150 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Final Category: High Grade Glioma/Gliomatosis Cerebri - HGG
Hu, Wanming
Yuan, Li
Zeng, Jing
HGG-01. INFANT-TYPE HEMISPHERIC GLIOMA: NEW MOLECULAR ALTERATIONS AND PRECISION-MEDICINE TREATMENT
title HGG-01. INFANT-TYPE HEMISPHERIC GLIOMA: NEW MOLECULAR ALTERATIONS AND PRECISION-MEDICINE TREATMENT
title_full HGG-01. INFANT-TYPE HEMISPHERIC GLIOMA: NEW MOLECULAR ALTERATIONS AND PRECISION-MEDICINE TREATMENT
title_fullStr HGG-01. INFANT-TYPE HEMISPHERIC GLIOMA: NEW MOLECULAR ALTERATIONS AND PRECISION-MEDICINE TREATMENT
title_full_unstemmed HGG-01. INFANT-TYPE HEMISPHERIC GLIOMA: NEW MOLECULAR ALTERATIONS AND PRECISION-MEDICINE TREATMENT
title_short HGG-01. INFANT-TYPE HEMISPHERIC GLIOMA: NEW MOLECULAR ALTERATIONS AND PRECISION-MEDICINE TREATMENT
title_sort hgg-01. infant-type hemispheric glioma: new molecular alterations and precision-medicine treatment
topic Final Category: High Grade Glioma/Gliomatosis Cerebri - HGG
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10260234/
http://dx.doi.org/10.1093/neuonc/noad073.150
work_keys_str_mv AT huwanming hgg01infanttypehemisphericgliomanewmolecularalterationsandprecisionmedicinetreatment
AT yuanli hgg01infanttypehemisphericgliomanewmolecularalterationsandprecisionmedicinetreatment
AT zengjing hgg01infanttypehemisphericgliomanewmolecularalterationsandprecisionmedicinetreatment